All In Biotech

Drug Trial Radar · NCT03340506

Dabrafenib and/or Trametinib Rollover Study

Open Label, Multi-center Roll-over Study to Assess Long Term Safety in Patients Who Have Completed a Global Novartis or GSK Sponsored Dabrafenib and/or Trametinib Study

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Jan 26, 2018

Primary completion

Dec 28, 2032

Study completion Dec 28, 2032

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Nov 13, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to provide access for patients who are receiving treatment with dabrafenib and/or trametinib in a Novartis-sponsored Oncology Global Development, Global Medical Affairs or a former GSK-sponsored study who have fulfilled the requirements for the primary objective, and who are judged by the investigator as benefiting from continued treatment in the parent study as judged by the Investigator at the completion of the parent study.

Conditions

  • Melanoma
  • Non Small Cell Lung Cancer
  • Solid Tumor
  • Rare Cancers
  • High Grade Glioma

Interventions

  • dabrafenibDrug

    dabrafenib is available in capsules (50mg and 75mg) taken twice a day

  • trametinibDrug

    trametinib is available in tablets (0.5mg, 2mg dose)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurences of adverse events to evaluate long term safety and tolerability of dabrafenib, trametinib or combinationTime frame: Baseline up to approximately 10 years after the first subject's first visit, or will remain open until treatment becomes commercially available and reimbursed, or another access program becomes available, whichever comes first.

Locations

37 sites in 15 countries. Site status is shown where the registry gives one.

  • Honor Health Research Institute

    Scottsdale, Arizona · Active not recruiting

  • National Institute Of Health

    Bethesda, Maryland · Active not recruiting

  • James Cancer Hospital and Solove Research Institute Ohio State

    Columbus, Ohio · Completed

  • Mary Crowley Cancer Research

    Dallas, Texas · Completed

  • Novartis Investigative Site

    Caba, Buenos Aires, Argentina · Completed

  • Novartis Investigative Site

    Innsbruck, Tyrol, Austria · Active not recruiting

  • Novartis Investigative Site

    Toronto, Ontario, Canada · Recruiting

  • Novartis Investigative Site

    Beijing, China · Completed

  • Novartis Investigative Site

    Brno, Czechia · Active not recruiting

  • Novartis Investigative Site

    Prague, Czechia · Active not recruiting

  • Novartis Investigative Site

    Copenhagen, Denmark · Active not recruiting

  • Novartis Investigative Site

    Lyon, France · Active not recruiting

  • Novartis Investigative Site

    Nantes, France · Completed

  • Novartis Investigative Site

    Paris, France · Active not recruiting

  • Novartis Investigative Site

    Paris, France · Completed

  • Novartis Investigative Site

    Villejuif, France · Recruiting

  • Novartis Investigative Site

    Augsburg, Germany · Active not recruiting

  • Novartis Investigative Site

    Berlin, Germany · Completed

  • Novartis Investigative Site

    Essen, Germany · Active not recruiting

  • Novartis Investigative Site

    Hamburg, Germany · Completed

  • Novartis Investigative Site

    Hamburg, Germany · Active not recruiting

  • Novartis Investigative Site

    Heidelberg, Germany · Active not recruiting

  • Novartis Investigative Site

    Mannheim, Baden-Wurttemberg, Germany · Completed

  • Novartis Investigative Site

    Budapest, Hungary · Completed

  • Novartis Investigative Site

    Debrecen, Hajdu Bihar Megye, Hungary · Completed

  • Novartis Investigative Site

    Kashiwa, Chiba, Japan · Completed

  • Novartis Investigative Site

    Chuo Ku, Tokyo, Japan · Completed

  • Novartis Investigative Site

    Utrecht, Netherlands · Active not recruiting

  • Novartis Investigative Site

    Rotterdam, South Holland, Netherlands · Completed

  • Novartis Investigative Site

    Moscow, Russia · Active not recruiting

  • Novartis Investigative Site

    Barcelona, Spain · Recruiting

  • Novartis Investigative Site

    Madrid, Spain · Active not recruiting

  • Novartis Investigative Site

    Madrid, Spain · Recruiting

  • Novartis Investigative Site

    Madrid, Spain · Completed

  • Novartis Investigative Site

    Madrid, Spain · Recruiting

  • Novartis Investigative Site

    Valencia, Spain · Active not recruiting

  • Novartis Investigative Site

    Songkhla, Hat Yai, Thailand · Active not recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.